Emerging Roles of the Atypical Chemokine Receptor 3 (ACKR3) in Cardiovascular Diseases
- PMID: 35846294
- PMCID: PMC9276939
- DOI: 10.3389/fendo.2022.906586
Emerging Roles of the Atypical Chemokine Receptor 3 (ACKR3) in Cardiovascular Diseases
Abstract
Chemokines, and their receptors play a crucial role in the pathophysiology of cardiovascular diseases (CVD). Chemokines classically mediate their effects by binding to G-protein-coupled receptors. The discovery that chemokines can also bind to atypical chemokine receptors (ACKRs) and initiate alternative signaling pathways has changed the paradigm regarding chemokine-related functions. Among these ACKRs, several studies have highlighted the exclusive role of ACKR3, previously known as C-X-C chemokine receptor type 7 (CXCR7), in CVD. Indeed, ACKR3 exert atheroprotective, cardioprotective and anti-thrombotic effects through a wide range of cells including endothelial cells, platelets, inflammatory cells, fibroblasts, vascular smooth muscle cells and cardiomyocytes. ACKR3 functions as a scavenger receptor notably for the pleiotropic chemokine CXCL12, but also as a activator of different pathways such as β-arrestin-mediated signaling or modulator of CXCR4 signaling through the formation of ACKR3-CXCR4 heterodimers. Hence, a better understanding of the precise roles of ACKR3 may pave the way towards the development of novel and improved therapeutic strategies for CVD. Here, we summarize the structural determinant characteristic of ACKR3, the molecules targeting this receptor and signaling pathways modulated by ACKR3. Finally, we present and discuss recent findings regarding the role of ACKR3 in CVD.
Keywords: ACKR3; atypical chemokine receptors; cardiovascular diseases; chemokine; signalling.
Copyright © 2022 Duval, Alayrac, Silvestre and Levoye.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures


References
-
- Back M, Weber C, Lutgens E. Regulation of Atherosclerotic Plaque Inflammation. J Intern Med (2015) 278:462–82. - PubMed
-
- Michel JB, Martin-Ventura JL, Nicoletti A, Ho-Tin-Noe B. Pathology of Human Plaque Vulnerability: Mechanisms and Consequences of Intraplaque Haemorrhages. Atherosclerosis (2014) 234:311–9. - PubMed
-
- Aifah A, Iwelunmor J, Akwanalo C, Allison J, Amberbir A, Asante KP, et al. . The Kathmandu Declaration on Global CVD/Hypertension Research and Implementation Science: A Framework to Advance Implementation Research for Cardiovascular and Other Noncommunicable Diseases in Low- and Middle-Income Countries. Glob Heart (2019) 14:103–7. - PMC - PubMed
-
- Gencer S, van der Vorst EPC, Aslani M, Weber C, Doring Y, Duchene J. Atypical Chemokine Receptors in Cardiovascular Disease. Thromb Haemost (2019) 119:534–41. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources